Do pentraxin 3 and neural pentraxin 2 have different facet function in hepatocellular carcinoma?

The long pentraxin (PTX) 3 and the neuronal pentraxin (NPTX) 2 has been found to exert pleiotropic roles in cancers due to their action in inflammation. However, the accurate clinical significance of PTX3 and NPTX2 in hepatocellular carcinoma (HCC), one of the commonest cancers in the world has not...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental medicine 2021-11, Vol.21 (4), p.555-562
Hauptverfasser: Cabiati, Manuela, Gaggini, Melania, De Simone, Paolo, Del Ry, Silvia
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 562
container_issue 4
container_start_page 555
container_title Clinical and experimental medicine
container_volume 21
creator Cabiati, Manuela
Gaggini, Melania
De Simone, Paolo
Del Ry, Silvia
description The long pentraxin (PTX) 3 and the neuronal pentraxin (NPTX) 2 has been found to exert pleiotropic roles in cancers due to their action in inflammation. However, the accurate clinical significance of PTX3 and NPTX2 in hepatocellular carcinoma (HCC), one of the commonest cancers in the world has not been well-defined. The aim of the study was to analyze the expression profile of PTX3 and NPTX2 in liver biopsies of HCV-positive HCC patients (liver recipients, LR, n  = 14, age 59.4 ± 1.8 years) undergoing liver transplantation and in donors (LD, n  = 14, age 62.1 ± 17.3 years), trying both to identify them as predictive biomarkers of clinical liver severity in HCC patients and to understand if they were mutually substitutable. The PTX3 and NPTX2 transcripts were significantly up regulated in HCC tissues ( p  = 0.004 and p  = 0.02 LD vs. LR, respectively). Dividing patients following MELD score, PTX3 expression increased as a function of liver disease severity, while this trend was not observed for NPTX2, which mRNA level increased similarly in both MELD group, reaching the significance only in patients with MELD score 
doi_str_mv 10.1007/s10238-021-00714-y
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2518970947</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2518970947</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-b83d868cf8a64e1ef33540404888942743f85b040637d5ab86d933715ecb344b3</originalsourceid><addsrcrecordid>eNp9kEtPxCAUhYnROOPjD7gwJG7cVKEXWroyZnwmk7jRNVJKnU5aWqE1zr-XseMjLgwJXC7fPZwchI4oOaOEpOeekhhERGIahStl0WoLTSnPaJTxWGxvaiEyMkF73i8JoVwA2UUTgIxwAnyKnq9a3BnbO_VeWQxY2QJbMzhV_2rHeKHeDC6qsjQudHGptAn7YHVftRYHZGE61bfa1PVQK4e1crqybaMuDtBOqWpvDjfnPnq6uX6c3UXzh9v72eU80pDyPsoFFCIRuhQqYYaaEoAzEpYI_lmcMigFz0MjgbTgKhdJkQGklBudA2M57KPTUbdz7etgfC-byq_9KGvawcuYU5GlJGNpQE_-oMt2cDa4C5QgmQDBWaDikdKu9d6ZUnauapRbSUrkOn855i9D_vIzf7kKQ8cb6SFvTPE98hV4AGAEfHiyL8b9_P2P7AdwOo96</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2580983854</pqid></control><display><type>article</type><title>Do pentraxin 3 and neural pentraxin 2 have different facet function in hepatocellular carcinoma?</title><source>MEDLINE</source><source>SpringerLink_现刊</source><creator>Cabiati, Manuela ; Gaggini, Melania ; De Simone, Paolo ; Del Ry, Silvia</creator><creatorcontrib>Cabiati, Manuela ; Gaggini, Melania ; De Simone, Paolo ; Del Ry, Silvia</creatorcontrib><description>The long pentraxin (PTX) 3 and the neuronal pentraxin (NPTX) 2 has been found to exert pleiotropic roles in cancers due to their action in inflammation. However, the accurate clinical significance of PTX3 and NPTX2 in hepatocellular carcinoma (HCC), one of the commonest cancers in the world has not been well-defined. The aim of the study was to analyze the expression profile of PTX3 and NPTX2 in liver biopsies of HCV-positive HCC patients (liver recipients, LR, n  = 14, age 59.4 ± 1.8 years) undergoing liver transplantation and in donors (LD, n  = 14, age 62.1 ± 17.3 years), trying both to identify them as predictive biomarkers of clinical liver severity in HCC patients and to understand if they were mutually substitutable. The PTX3 and NPTX2 transcripts were significantly up regulated in HCC tissues ( p  = 0.004 and p  = 0.02 LD vs. LR, respectively). Dividing patients following MELD score, PTX3 expression increased as a function of liver disease severity, while this trend was not observed for NPTX2, which mRNA level increased similarly in both MELD group, reaching the significance only in patients with MELD score &lt; 9 ( p  = 0.01). A positive correlation was found between PTX3 and NPTX2 expression ( p  = 0.001; r  = 0.69). This is the first study that concerns PTX3 and NPTX2 as a function of clinical severity from which emerged that both of them are unequivocally involved in HCC, but only PTX3 could be considered a staging marker in these HCV-related HCC patients, unlike NPTX2, which could only play a role as an inflammatory marker.</description><identifier>ISSN: 1591-8890</identifier><identifier>EISSN: 1591-9528</identifier><identifier>DOI: 10.1007/s10238-021-00714-y</identifier><identifier>PMID: 33905035</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adult ; Aged ; Biomarkers ; Biopsy ; C-Reactive Protein ; Carcinoma, Hepatocellular ; Hematology ; Hepatocellular carcinoma ; Humans ; Inflammation ; Internal Medicine ; Liver cancer ; Liver diseases ; Liver Neoplasms ; Liver transplantation ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Nerve Tissue Proteins ; Oncology ; Original Article ; Patients ; Pentraxins ; Serum Amyloid P-Component</subject><ispartof>Clinical and experimental medicine, 2021-11, Vol.21 (4), p.555-562</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</rights><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-b83d868cf8a64e1ef33540404888942743f85b040637d5ab86d933715ecb344b3</citedby><cites>FETCH-LOGICAL-c375t-b83d868cf8a64e1ef33540404888942743f85b040637d5ab86d933715ecb344b3</cites><orcidid>0000-0002-0811-6257</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10238-021-00714-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10238-021-00714-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33905035$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cabiati, Manuela</creatorcontrib><creatorcontrib>Gaggini, Melania</creatorcontrib><creatorcontrib>De Simone, Paolo</creatorcontrib><creatorcontrib>Del Ry, Silvia</creatorcontrib><title>Do pentraxin 3 and neural pentraxin 2 have different facet function in hepatocellular carcinoma?</title><title>Clinical and experimental medicine</title><addtitle>Clin Exp Med</addtitle><addtitle>Clin Exp Med</addtitle><description>The long pentraxin (PTX) 3 and the neuronal pentraxin (NPTX) 2 has been found to exert pleiotropic roles in cancers due to their action in inflammation. However, the accurate clinical significance of PTX3 and NPTX2 in hepatocellular carcinoma (HCC), one of the commonest cancers in the world has not been well-defined. The aim of the study was to analyze the expression profile of PTX3 and NPTX2 in liver biopsies of HCV-positive HCC patients (liver recipients, LR, n  = 14, age 59.4 ± 1.8 years) undergoing liver transplantation and in donors (LD, n  = 14, age 62.1 ± 17.3 years), trying both to identify them as predictive biomarkers of clinical liver severity in HCC patients and to understand if they were mutually substitutable. The PTX3 and NPTX2 transcripts were significantly up regulated in HCC tissues ( p  = 0.004 and p  = 0.02 LD vs. LR, respectively). Dividing patients following MELD score, PTX3 expression increased as a function of liver disease severity, while this trend was not observed for NPTX2, which mRNA level increased similarly in both MELD group, reaching the significance only in patients with MELD score &lt; 9 ( p  = 0.01). A positive correlation was found between PTX3 and NPTX2 expression ( p  = 0.001; r  = 0.69). This is the first study that concerns PTX3 and NPTX2 as a function of clinical severity from which emerged that both of them are unequivocally involved in HCC, but only PTX3 could be considered a staging marker in these HCV-related HCC patients, unlike NPTX2, which could only play a role as an inflammatory marker.</description><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers</subject><subject>Biopsy</subject><subject>C-Reactive Protein</subject><subject>Carcinoma, Hepatocellular</subject><subject>Hematology</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Internal Medicine</subject><subject>Liver cancer</subject><subject>Liver diseases</subject><subject>Liver Neoplasms</subject><subject>Liver transplantation</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Nerve Tissue Proteins</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Patients</subject><subject>Pentraxins</subject><subject>Serum Amyloid P-Component</subject><issn>1591-8890</issn><issn>1591-9528</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtPxCAUhYnROOPjD7gwJG7cVKEXWroyZnwmk7jRNVJKnU5aWqE1zr-XseMjLgwJXC7fPZwchI4oOaOEpOeekhhERGIahStl0WoLTSnPaJTxWGxvaiEyMkF73i8JoVwA2UUTgIxwAnyKnq9a3BnbO_VeWQxY2QJbMzhV_2rHeKHeDC6qsjQudHGptAn7YHVftRYHZGE61bfa1PVQK4e1crqybaMuDtBOqWpvDjfnPnq6uX6c3UXzh9v72eU80pDyPsoFFCIRuhQqYYaaEoAzEpYI_lmcMigFz0MjgbTgKhdJkQGklBudA2M57KPTUbdz7etgfC-byq_9KGvawcuYU5GlJGNpQE_-oMt2cDa4C5QgmQDBWaDikdKu9d6ZUnauapRbSUrkOn855i9D_vIzf7kKQ8cb6SFvTPE98hV4AGAEfHiyL8b9_P2P7AdwOo96</recordid><startdate>20211101</startdate><enddate>20211101</enddate><creator>Cabiati, Manuela</creator><creator>Gaggini, Melania</creator><creator>De Simone, Paolo</creator><creator>Del Ry, Silvia</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0811-6257</orcidid></search><sort><creationdate>20211101</creationdate><title>Do pentraxin 3 and neural pentraxin 2 have different facet function in hepatocellular carcinoma?</title><author>Cabiati, Manuela ; Gaggini, Melania ; De Simone, Paolo ; Del Ry, Silvia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-b83d868cf8a64e1ef33540404888942743f85b040637d5ab86d933715ecb344b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers</topic><topic>Biopsy</topic><topic>C-Reactive Protein</topic><topic>Carcinoma, Hepatocellular</topic><topic>Hematology</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Internal Medicine</topic><topic>Liver cancer</topic><topic>Liver diseases</topic><topic>Liver Neoplasms</topic><topic>Liver transplantation</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Nerve Tissue Proteins</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Patients</topic><topic>Pentraxins</topic><topic>Serum Amyloid P-Component</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cabiati, Manuela</creatorcontrib><creatorcontrib>Gaggini, Melania</creatorcontrib><creatorcontrib>De Simone, Paolo</creatorcontrib><creatorcontrib>Del Ry, Silvia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cabiati, Manuela</au><au>Gaggini, Melania</au><au>De Simone, Paolo</au><au>Del Ry, Silvia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Do pentraxin 3 and neural pentraxin 2 have different facet function in hepatocellular carcinoma?</atitle><jtitle>Clinical and experimental medicine</jtitle><stitle>Clin Exp Med</stitle><addtitle>Clin Exp Med</addtitle><date>2021-11-01</date><risdate>2021</risdate><volume>21</volume><issue>4</issue><spage>555</spage><epage>562</epage><pages>555-562</pages><issn>1591-8890</issn><eissn>1591-9528</eissn><abstract>The long pentraxin (PTX) 3 and the neuronal pentraxin (NPTX) 2 has been found to exert pleiotropic roles in cancers due to their action in inflammation. However, the accurate clinical significance of PTX3 and NPTX2 in hepatocellular carcinoma (HCC), one of the commonest cancers in the world has not been well-defined. The aim of the study was to analyze the expression profile of PTX3 and NPTX2 in liver biopsies of HCV-positive HCC patients (liver recipients, LR, n  = 14, age 59.4 ± 1.8 years) undergoing liver transplantation and in donors (LD, n  = 14, age 62.1 ± 17.3 years), trying both to identify them as predictive biomarkers of clinical liver severity in HCC patients and to understand if they were mutually substitutable. The PTX3 and NPTX2 transcripts were significantly up regulated in HCC tissues ( p  = 0.004 and p  = 0.02 LD vs. LR, respectively). Dividing patients following MELD score, PTX3 expression increased as a function of liver disease severity, while this trend was not observed for NPTX2, which mRNA level increased similarly in both MELD group, reaching the significance only in patients with MELD score &lt; 9 ( p  = 0.01). A positive correlation was found between PTX3 and NPTX2 expression ( p  = 0.001; r  = 0.69). This is the first study that concerns PTX3 and NPTX2 as a function of clinical severity from which emerged that both of them are unequivocally involved in HCC, but only PTX3 could be considered a staging marker in these HCV-related HCC patients, unlike NPTX2, which could only play a role as an inflammatory marker.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>33905035</pmid><doi>10.1007/s10238-021-00714-y</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-0811-6257</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1591-8890
ispartof Clinical and experimental medicine, 2021-11, Vol.21 (4), p.555-562
issn 1591-8890
1591-9528
language eng
recordid cdi_proquest_miscellaneous_2518970947
source MEDLINE; SpringerLink_现刊
subjects Adult
Aged
Biomarkers
Biopsy
C-Reactive Protein
Carcinoma, Hepatocellular
Hematology
Hepatocellular carcinoma
Humans
Inflammation
Internal Medicine
Liver cancer
Liver diseases
Liver Neoplasms
Liver transplantation
Medicine
Medicine & Public Health
Middle Aged
Nerve Tissue Proteins
Oncology
Original Article
Patients
Pentraxins
Serum Amyloid P-Component
title Do pentraxin 3 and neural pentraxin 2 have different facet function in hepatocellular carcinoma?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T06%3A28%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Do%20pentraxin%203%20and%20neural%20pentraxin%202%20have%20different%20facet%20function%20in%20hepatocellular%20carcinoma?&rft.jtitle=Clinical%20and%20experimental%20medicine&rft.au=Cabiati,%20Manuela&rft.date=2021-11-01&rft.volume=21&rft.issue=4&rft.spage=555&rft.epage=562&rft.pages=555-562&rft.issn=1591-8890&rft.eissn=1591-9528&rft_id=info:doi/10.1007/s10238-021-00714-y&rft_dat=%3Cproquest_cross%3E2518970947%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2580983854&rft_id=info:pmid/33905035&rfr_iscdi=true